Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xenon Pharmaceuticals Inc XENE

Healthcare Biotechnology
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the... see more

Recent & Breaking News (NDAQ:XENE)

Xenon Pharmaceuticals Reports 2015 Financial Results and Provides Corporate Update

GlobeNewswire March 8, 2016

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2015 Financial Results and Provide Corporate Update

GlobeNewswire March 1, 2016

Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne

GlobeNewswire February 10, 2016

Xenon Names Dr. James R. Empfield Senior Vice President, Drug Discovery

GlobeNewswire February 9, 2016

Xenon Outlines Key Milestones for 2016

GlobeNewswire January 11, 2016

Xenon and Genentech Publish in Science the 3-D Crystal Structure of a Novel Nav1.7 Compound Binding Site Enabling the Development of Potent Selective Inhibitors to Treat Pain

GlobeNewswire December 17, 2015

Xenon Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference

GlobeNewswire November 12, 2015

Xenon Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update

GlobeNewswire November 10, 2015

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2015 Financial Results and Provide Corporate Update

GlobeNewswire November 5, 2015

Xenon Announces Its Partner Genentech Has Advanced GDC-0310, a Second Nav1.7 Inhibitor for Pain, Into Clinical Development

GlobeNewswire October 22, 2015

Xenon Pharmaceuticals Announces Initiation of XEN801 Phase 1 Clinical Trial

GlobeNewswire September 24, 2015

Xenon Pharmaceuticals Achieves Milestone in Genentech Collaboration to Discover Novel Pain Targets

GlobeNewswire September 21, 2015

Xenon Pharmaceuticals to Present at the 10th Annual Wells Fargo Healthcare Conference

GlobeNewswire September 3, 2015

Xenon Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update

GlobeNewswire August 10, 2015

Xenon Pharmaceuticals to Present at the Canaccord Genuity 35th Annual Growth Conference

GlobeNewswire August 6, 2015

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2015 Financial Results and Provide Corporate Update

GlobeNewswire August 5, 2015

Xenon Pharmaceuticals to Host Conference Call and Webcast Today at 9:00 a.m. Eastern Time to Discuss TV-45070 Phase 2b Study in Osteoarthritis Pain

GlobeNewswire July 1, 2015

Teva and Xenon Provide Update on TV-45070 Phase 2b Study in Osteoarthritis Pain

GlobeNewswire July 1, 2015

Teva and Xenon Provide Update on TV-45070 Phase 2b Study in Osteoarthritis Pain

Business Wire July 1, 2015

Xenon Pharmaceuticals to Provide Business and Milestone Update at Jefferies 2015 Global Healthcare Conference

GlobeNewswire May 28, 2015